ROIV Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
1.4M
-42.8%
2.5M
+26.1%
2.0M
+27.2%
1.6M
-27.6%
2.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.4M
-42.8%
2.5M
+26.1%
2.0M
+27.2%
1.6M
-27.6%
2.2M
Operating Expenses
367.4M
+189.0%
-412720000
-221.0%
341.2M
+10.8%
307.8M
+7.2%
287.1M
R&D
202.0M
+1.5%
198.9M
+20.3%
165.4M
+0.5%
164.6M
+7.6%
152.9M
SG&A
165.5M
+4.6%
158.3M
-9.6%
175.1M
+22.3%
143.1M
+6.8%
134.0M
Operating Income
-365993000
-188.1%
415.2M
+222.4%
-339153000
-10.7%
-306233000
-7.5%
-284922000
EBITDA
-365785000
-3.2%
-354357000
-4.7%
-338462000
-10.9%
-305312000
-7.6%
-283824000
Net Income
-290606000
-181.7%
355.7M
+213.4%
-313701000
-88.9%
-166039000
+39.4%
-273911000
EPS (Basic)
$-0.26
-161.9%
$0.42
+210.5%
$-0.38
-123.5%
$-0.17
+48.5%
$-0.33
EPS (Diluted)
$-0.26
-161.9%
$0.42
+210.5%
$-0.38
-123.5%
$-0.17
+48.5%
$-0.33
Shares (Diluted)
720.8M
+0.5%
717.4M
+2.9%
696.9M
+2.3%
680.9M
+0.1%
680.3M
Roivant Sciences Ltd. Common Shares (ROIV) โ€” Financials